Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nucleosome Remodeling02:54

Nucleosome Remodeling

10.1K
Nucleosomes are the basic units of chromatin compaction. Each nucleosome consists of the DNA bound tightly around a histone core, which makes the DNA inaccessible to DNA binding proteins such as DNA polymerase and RNA polymerase. Hence, the fundamental problem is to ensure access to DNA when appropriate, despite the compact and protective chromatin structure.
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
10.1K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

2.0K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
2.0K
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

8.9K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
8.9K
Cranial and Spinal Meninges01:19

Cranial and Spinal Meninges

2.6K
The cranial and spinal meninges are complex protective structures surrounding the central nervous system (CNS), consisting of the brain and spinal cord. These meninges consist of the dura mater, the arachnoid mater, and the pia mater. They protect the CNS, provide structural support, and aid in circulating cerebrospinal fluid (CSF).
Cranial Meninges
These meningeal layers cover the cranium. The dura mater is the outermost layer of cranial meninges. It is a thick and durable membrane of dense...
2.6K
Inheritance of Chromatin Structures03:17

Inheritance of Chromatin Structures

6.9K
Epigenetics is the study of inherited changes in a cell's phenotype without changing the DNA sequences. It provides a form of memory for the differential gene expression pattern to maintain cell lineage, position-effect variegation, dosage compensation, and maintenance of chromatin structures such as telomeres and centromeres. For example, the structure and location of the centromere on chromosomes are epigenetically inherited. Its functionality is not dictated or ensured by the underlying...
6.9K
The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

3.4K
The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histopathological and molecular heterogeneity of dysembryoplastic neuroepithelial tumors.

Journal of neuropathology and experimental neurology·2026
Same author

Residual tumor volume guides post-surgical treatment paradigm and need for salvage radiotherapy in vestibular schwannoma management.

Journal of neuro-oncology·2026
Same author

A Mixed-Methods Study of Policymakers' Adoption of AI to Support Use of Research Evidence: Implications for Artificial Intelligence in Prevention Policy.

Prevention science : the official journal of the Society for Prevention Research·2026
Same author

Expanding the molecular grading criteria in IDH-mutant astrocytoma.

Neuro-oncology·2026
Same author

Right medial temporal lobe mass in a 25-year-old male.

Brain pathology (Zurich, Switzerland)·2026
Same author

Correction: Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Nov 13, 2025

Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres
09:31

Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres

Published on: January 29, 2018

7.9K

SWI/SNF chromatin remodeling complex alterations in meningioma.

Corey M Gill1, Joshua Loewenstern2, John W Rutland2

  • 1Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. corey.gill@icahn.mssm.edu.

Journal of Cancer Research and Clinical Oncology
|March 14, 2021
PubMed
Summary

SWI/SNF chromatin remodeling complex gene alterations, particularly ARID1A mutations, are common in meningiomas. These ARID1A mutations independently predict a worse prognosis, regardless of tumor grade.

Keywords:
ARID1AChromatin remodelingEpigeneticGenomicMeningiomaSWI/SNF

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.4K
CD Spectroscopy to Study DNA-Protein Interactions
06:48

CD Spectroscopy to Study DNA-Protein Interactions

Published on: February 10, 2022

7.3K

Related Experiment Videos

Last Updated: Nov 13, 2025

Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres
09:31

Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres

Published on: January 29, 2018

7.9K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.4K
CD Spectroscopy to Study DNA-Protein Interactions
06:48

CD Spectroscopy to Study DNA-Protein Interactions

Published on: February 10, 2022

7.3K

Area of Science:

  • Neuro-oncology
  • Cancer genomics
  • Tumorigenesis

Background:

  • Alterations in SWI/SNF chromatin remodeling complexes are implicated in approximately 20% of cancers.
  • The specific frequency and clinical impact of these alterations in meningiomas are not well-understood.

Purpose of the Study:

  • To investigate the frequency of SWI/SNF gene mutations in a large cohort of meningiomas.
  • To determine the association between these mutations and clinical outcomes, including tumor grade and patient survival.

Main Methods:

  • Targeted next-generation sequencing of key meningioma driver genes and SWI/SNF complex genes (ARID1A, SMARCA4, SMARCB1) in 255 meningioma samples.
  • Analysis of clinical data, including tumor grade, recurrence status, and patient survival.

Main Results:

  • ARID1A mutations were found in 17.3% of meningiomas, with similar frequencies across WHO grades I, II, and III.
  • A specific in-frame deletion (p.Gln1327del) was common in ARID1A-mutant tumors.
  • ARID1A mutations were significantly associated with a 7.4-fold increased hazard of death (P=0.04) in multivariable analysis.

Conclusions:

  • ARID1A mutations are prevalent in meningiomas and occur at similar rates in both low- and high-grade tumors.
  • ARID1A mutations serve as an independent prognostic marker for worse outcomes in meningioma patients.